Comprehensive analysis of T cell immunodominance
and immunoprevalence of SARS-CoV-2 epitopes in
COVID-19 cases

#	Paper	IF	Citations
347	Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers. **2021**,		1
346	How 'killer' T cells could boost COVID immunity in face of new variants. **2021**, 590, 374-375		22
345	A single-cell atlas of lymphocyte adaptive immune repertoires and transcriptomes reveals age-related differences in convalescent COVID-19 patients.		0
344	CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. **2021**,		13
343	Adaptive immunity to SARS-CoV-2 and COVID-19. **2021**, 184, 861-880		519
342	SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response.		1
341	Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. **2021**, 593, 142-146		344
340	Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. **2021**, 10, 196		2
339	Negligible impact of SARS-CoV-2 variants on CD4 and CD8 T cell reactivity in COVID-19 exposed donors and vaccinees. **2021**,		81
338	A novel whole-blood stimulation assay to detect and quantify memory T-cells in COVID-19 patients.		0
337	SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 T cell responses. **2021**, 6,		58
336	Evolutionary and phenotypic characterization of spike mutations in a new SARS-CoV-2 Lineage reveals two Variants of Interest.		
335	Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2.		0
334	New SARS-CoV-2 lineages could evade CD8+ T-cells response.		4
333	The great escape? SARS-CoV-2 variants evading neutralizing responses. **2021**, 29, 322-324		48
332	Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. **2021**, 224, 39-48		20
331	CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. **2021**, 8, ofab143		44

330	CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2.	3
329	Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis. **2021**, 10,	6
328	Insertions in SARS-CoV-2 genome caused by template switch and duplications give rise to new variants of potential concern. **2021**,	2
327	Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination.	15
326	T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. **2021**, 13,	54
325	Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach. **2021**, 13,	3
324	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. **2021**, 131,	65
323	Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during COVID-19 convalescence. **2021**,	3
322	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein.	3
321	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. **2021**, 15, 5793-5818	13
320	Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. **2021**, 224, 70-80	14
319	SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 T cell activation in COVID-19 patients. **2021**, 6,	65
318	Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination.	3
317	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. **2021**, 42, 312-322	35
316	Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. **2021**, 11, 1982-1995	12
315	SARS-CoV-2 Spike-Derived Peptides Presented by HLA Molecules. **2021**, 1, 194-203	1
314	[Reinfection by SARS-CoV-2: The first one in a family reported in Spain]. **2021**, 157, e321-e323	2
313	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition. *Cell Reports Medicine*, **2021**, 2, 100286	18 6

312	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. **2021**, 35, 109179		20
311	Vaccinating children against SARS-CoV-2. **2021**, 373, n1197		10
310	Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. **2021**, 372, 1336-1341		33
309	Analysis and visualization of epidemics on the timescale of burden: derivation and application of Epidemic Resistance Lines (ERLs) to COVID-19 outbreaks in the US.		1
308	Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform. *Cell Reports Medicine*, **2021**, 2, 100312	18	13
307	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure.		10
306	A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. **2021**, 12, 684152		1
305	The polarity and specificity of SARS-CoV2-specific T lymphocyte responses determine disease susceptibility.		
304	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. **2021**, 224, 1109-1114		26
303	Landscape and selection of vaccine epitopes in SARS-CoV-2. **2021**, 13, 101		10
302	Human CD4 T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. **2021**, 205, 363-378		7
301	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. **2021**, 9,		2
300	Predicting the mutational drivers of future SARS-CoV-2 variants of concern.		6
299	Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19â55 years.		0
298	SARS-CoV-2-specific CD8 T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. **2021**, 99, 990-1000		4
297	Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.		23
296	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. **2021**, 9,		3
295	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. **2021**, 12, 4048		17

294	Whole blood-based measurement of SARS-CoV-2-specific T cell responses reveals asymptomatic infection and vaccine efficacy in healthy subjects and patients with solid organ cancers.	0
293	Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations. **2021**, 27, 823-826	14
292	The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA supertype-dependent manner.	0
291	SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization.	7
290	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. **2021**, 27, 1784-1789	15
289	SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. **2021**, 29, 1076-1092	59
288	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. **2021**, 184, 3962-3980.e17	17
287	HLA-dependent variation in SARS-CoV-2 CD8+ T cell cross-reactivity with human coronaviruses.	1
286	Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. **2021**, 12, 669357	3
285	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. **2021**, 29, 1093-1110	19
284	Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals. *Cell Reports Medicine*, **2021**, 2, 100355	18	194
283	Recruitment of highly functional SARS-CoV-2-specific CD8+ T cell receptors mediating cytotoxicity of virus-infected target cells in non-severe COVID-19.	0
282	Impaired Priming of SARS-CoV-2-Specific Naive CD8 T Cells in Older Subjects. **2021**, 12, 693054	4
281	Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors.	1
280	Allotypic variation in antigen processing controls antigenic peptide generation from SARS-CoV-2 S1 Spike Glycoprotein.	
279	Predicted Impact of the Viral Mutational Landscape on the Cytotoxic Response against SARS-CoV-2.	0
278	Severity of SARS-CoV-2 reinfections in second wave determines likelihood of mild endemicity.	1
277	Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination. **2021**,	6

276	A Single-Cell Atlas of Lymphocyte Adaptive Immune Repertoires and Transcriptomes Reveals Age-Related Differences in Convalescent COVID-19 Patients. **2021**, 12, 701085	9
275	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection.	13
274	Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. **2021**, 8, 675963	1
273	Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q.	4
272	mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. **2021**,	23
271	Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. **2021**, 374, eabh1823	53
270	Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.	0
269	Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8 T Cells during Convalescence. **2021**, 207, 1344-1356	7
268	Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection.	1
267	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. **2021**, 13,	21
266	Picture of the Favourable Immune Profile Induced by Anti-SARS-CoV-2 Vaccination. **2021**, 9,	2
265	PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage. **2021**, 12, 728936	1
264	SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-derived Immunoglobulin.	
263	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. **2021**, 199-225	3
262	Exploring COVID-19 at the single-cell level. **2021**, Publish Ahead of Print,	
261	SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage. **2021**, 12, 705772	7
260	Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines. **2021**, 9,	7
259	Molecular basis of a dominant SARS-CoV-2 Spike-derived epitope presented by HLA-A*02:01 recognised by a public TCR.	0

258	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. **2021**, 27, 1990-2001	138
257	An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest. **2021**, 136, 104703	3
256	Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. **2021**, 12, 730051	2
255	Design of T cell epitope-based vaccine candidate for SARS-CoV-2 targeting nucleocapsid and spike protein escape variants.	0
254	Profiling CD8 T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. **2021**, 36, 109708	9
253	Design of Peptide Vaccine for COVID19: CD8+ and CD4+ T cell epitopes from SARS-CoV-2 open-reading-frame protein variants.	0
252	Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines. **2021**, 12, 732450	2
251	The biological and clinical significance of emerging SARS-CoV-2 variants. **2021**, 22, 757-773	175
250	Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. **2021**, 17, e1009842	6
249	Rapid induction of antigen-specific CD4 T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. **2021**, 54, 2133-2142.e3	117
248	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. **2021**, 131,	20
247	SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans.	7
246	Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. **2021**, 16, e0249254	9
245	Neutralizing antibody-independent immunity to SARS-CoV-2 in hamsters and hACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion protein.	1
244	Performance of the T-SPOT.COVID test for detecting SARS-CoV-2-responsive T cells. **2021**, 113, 155-161	6
243	A flow cytometry-based proliferation assay for clinical evaluation of T-cell memory against SARS-CoV-2. **2021**, 499, 113159	0
242	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. **2021**, 2,	23
241	SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey. **2021**, 14, 894-947	

| 240 | BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease. **2021**, 9, | 3 |

| 239 | mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. **2021**, 374, abm0829 | 133 |

| 238 | Allotypic variation in antigen processing controls antigenic peptide generation from SARS-CoV-2 S1 spike glycoprotein. **2021**, 297, 101329 | 1 |

| 237 | Public T-cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles. | 0 |

| 236 | Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. **2021**, 9, 1450-1466 | 31 |

| 235 | Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection. **2021**, | 4 |

| 234 | The mutational landscape of SARS-CoV-2 variants diversifies Tcell targets in an HLA-supertype-dependent manner. **2021**, | 6 |

| 233 | Molecular Basis of a Dominant SARS-CoV-2 Spike-Derived Epitope Presented by HLA-A*02:01 Recognised by a Public TCR. **2021**, 10, | 0 |

| 232 | The COVID-19 pandemic: viral variants and vaccine efficacy. **2021**, 1-10 | 10 |

| 231 | Limited impact of Delta variant mutations in the effectiveness of neutralization conferred by natural infection or COVID-19 vaccines in a Latino population. **2021**, | |

| 230 | In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles. | |

| 229 | Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. | 1 |

| 228 | Designing of cytotoxic T lymphocyte-based multi-epitope vaccine against SARS-CoV2: a reverse vaccinology approach. **2021**, 1-16 | 0 |

| 227 | Tracking SARS-CoV-2 T cells with epitope-T-cell receptor recognition models. | |

| 226 | Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. **2021**, 6, 128 | 13 |

| 225 | Immunology and controlling of coronaviruses; the current enemy for humanity: A review. **2021**, | 1 |

| 224 | Reinfection by SARS-CoV-2: The first one in a family reported in Spain. **2021**, 157, e321-e323 | |

| 223 | Using animal models for studying SARS-CoV-2. **2021**, 1-17 | 2 |

204   Recruitment of highly cytotoxic CD8 T cell receptors in mild SARS-CoV-2 infection.. **2021**, 110214   1

203   SARS-CoV-2-specific T cell responses and immune regulation in infected pregnant women.. **2021**, 149, 103464   1

202   Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.. **2022**, 20, 26   21

201   T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant.. **2022**,   13

200   SARS-CoV-2 Variants, Vaccines, and Host Immunity.. **2021**, 12, 809244   24

199   Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors.. **2022**, 13, 19   1

198   T cell responses to SARS-CoV-2 spike cross-recognize Omicron.. **2022**,   78

197   Broadly-recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles.   0

196   Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.. **2022**,   1

195   Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.   1

194   Three Specific Potential Epitopes That Could Be Recognized by T Cells of Convalescent COVID-19 Patients Were Identified From Spike Protein.. **2022**, 13, 752622   0

193   T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components.. **2022**,

192   SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.. **2022**,   75

191   Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2.. **2021**, 12, 812176   2

190   Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2.. **2022**, 103,   0

189   Predicting the mutational drivers of future SARS-CoV-2 variants of concern.. **2022**, 14, eabk3445   9

188   Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.. **2022**,   4

187   Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults.   0

186	Imprinted SARS-CoV-2-Specific Memory Lymphocytes Define Hybrid Immunity.	
185	Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria.. **2022**, 13, 821595	0
184	The T cell immune response against SARS-CoV-2.. **2022**, 23, 186-193	63
183	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.. **2022**, 15, 277-288	2
182	Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions.. **2022**, 103850	0
181	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein.. **2022**, 310, 198674	4
180	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.. **2022**, 209, 112816	27
179	Predicted impact of the viral mutational landscape on the cytotoxic response against SARS-CoV-2.. **2022**, 18, e1009726	1
178	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.. **2022**,	3
177	In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape.. **2022**, 105236	1
176	Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status.. **2022**,	0
175	T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components.. **2022**,	1
174	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. **2022**, 14,	14
173	HLA-dependent variation in SARS-CoV-2 CD8+ T cell cross-reactivity with human coronaviruses.. **2022**,	3
172	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).. **2021**, 51, 2708-3145	12
171	The germinal centre B cell response to SARS-CoV-2. **2021**,	17
170	SARS-CoV-2 T cell responses are expected to remain robust against Omicron.	5
169	SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron.	11

168	Allelic variation in class I HLA determines CD8 T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. **2021**, eabk3070	4
167	SARS-CoV-2 peptide vaccine elicits T-cell responses in mice but does not protect against infection or disease.	1
166	Frequencies and TCR Repertoires of Human 2,4,6-Trinitrobenzenesulfonic Acid-specific T Cells.. **2022**, 4, 827109	0
165	POST-ACUTE SEQUELAE AND ADAPTIVE IMMUNE RESPONSES IN PEOPLE LIVING WITH HIV RECOVERING FROM SARS-COV-2 INFECTION.	0
164	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice.. **2022**, 7, 23	2
163	The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals.. **2022**,	2
162	In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles.. **2022**, 8, eabm7950	1
161	COVID-19 Pandemic: Escape of Pathogenic Variants and MHC Evolution.. **2022**, 23,	0
160	Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2.	0
159	SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.. **2021**,	22
158	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection.. **2022**,	1
157	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review.. **2022**, 13, 835104	2
156	Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss In Spike.	
155	Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.. **2022**,	13
154	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.. **2022**, e0297921	12
153	SARS-CoV-2 variant B.1.1.7 caused HLA-A2 CD8 T cell epitope mutations for impaired cellular immune response.. **2022**, 25, 103934	1
152	Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.. **2022**, 23,	0
151	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4 T cell memory.. **2022**,	3

150	Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?. **2022**, 27,	3
149	COVID-19 vaccination: The road ahead.. **2022**, 375, 1127-1132	13
148	Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period.. **2022**,	0
147	Rapid Screen for Anti-viral T-cell Immunity with Nanowire Electrochemical Biosensors.. **2022**, e2109661	1
146	CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.. **2022**, 17, e0266691	
145	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.. **2022**,	1
144	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells.. **2022**,	7
143	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine.	
142	Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.. **2021**, 17, e1010203	3
141	HLA-A02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.. **2021**, 37, 110167	1
140	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.	1
139	Distinguishing COVID-19 infection and vaccination history by T cell reactivity.	1
138	A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.. **2021**, 17, e1010092	2
137	Evidence of SARS-CoV-2-Specific T-Cell-Mediated Myocarditis in a MIS-A Case.. **2021**, 12, 779026	0
136	CHARM: COVID-19 Health Action Response for Marines â association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.	
135	Level and duration of IgG and neutralizing antibodies to SARS-CoV-2 in children with symptomatic or asymptomatic SARS-CoV-2 infection.	
134	Observations and perspectives on adaptive immunity to SARS-CoV-2.. **2022**,	0
133	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell mediated immunity.. **2022**,	0

132	Longitudinal analysis of T-cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection.. **2022**,	0
131	SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals.. **2022**,	2
130	High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape.. **2022**, 8, eabl5394	0
129	Adaptive Immune Responses and Immunity to SARS-CoV-2. **2022**, 13,	3
128	SARS-CoV-2 variants do not evolve to promote further escape from MHC-I recognition.. **2022**,	2
127	T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. **2022**, 13,	1
126	SARS-CoV-2 Omicron variant escapes neutralising antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.. *Cell Reports Medicine*, **2022**, 100651	18 1
125	Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age.	
124	Modeling suggests that multiple immunizations or infections will reveal the benefits of updating SARS-CoV-2 vaccines.	
123	Bioinformatic and Experimental Analysis of T Cell Immune Reactivity to SARS-CoV-2 and its Variants. **2022**, 2,	1
122	Three-doses of BNT162b2 COVID-19 mRNA vaccine establishes long-lasting CD8+ T cell immunity in CLL and MDS patients.	
121	Predictions of immunogenicity reveal potent SARS-CoV-2 CD8+ T-cell epitopes.	0
120	Could a Lower Toll-like Receptor (TLR) and NF-**B** Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. **2022**, 23, 5966	2
119	Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles. **2022**, 110952	1
118	Correlates of protection against SARS - CoV -2 infection and COVID-19 disease.	6
117	T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3, and GKA).	2
116	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. **2022**, 10, 904	0
115	A streamlined platform for analyzing tera-scale DDA and DIA mass spectrometry data enables highly sensitive immunopeptidomics. **2022**, 13,	0

114	Level and Duration of IgG and Neutralizing Antibodies to SARS-CoV-2 in Children with Symptomatic or Asymptomatic SARS-CoV-2 Infection. **2022**, 6, 408-415	1
113	Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike. 13,	
112	Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants Determined by Rapid Cytokine Release Assay in Whole Blood. **2022**, 6, 398-407	
111	Immunological memory to SARS-CoV -2 infection and COVID -19 vaccines.	12
110	Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals. 13,	0
109	Cellular Immunity in the Patients with COVID-19: Molecular Biology, Pathophysiology, and Clinical Implications.	
108	The T cell epitope landscape of SARS-CoV-2 variants of concern.	0
107	On the origin of Omicron's unique Spike gene insertion.	2
106	Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 VaccinesâEffectiveness in Delta Variant Breakthrough Infections. **2022**, 14, 1385	1
105	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. 13,	1
104	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. **2022**, 23, 7155	2
103	The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern. **2022**, 10, 1123	0
102	An immunological autobiography: my year as a COVID-19 vaccine trial participant. **2022**, 7,	
101	PERSISTENT IMMUNITY AFTER MILD SARS CoV-2 INFECTION - THE CoNAN-LONG TERM STUDY -.	
100	Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery. *Cell Reports Medicine*, **2022**, 100697	18	1
99	Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. 13,	1
98	Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector. **2022**, 10, 1142	0
97	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. 11,	1

| 96 | Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals. **2022**, 14, 1570 | 1 |

| 95 | Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-COV-2 infection. Publish Ahead of Print, | o |

| 94 | Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. **2022**, | o |

| 93 | A universal SARS-CoV DNA vaccine inducing highly crossreactive neutralizing antibodies and T cells. | 3 |

| 92 | Current Vaccine Platforms in Enhancing T-Cell Response. **2022**, 10, 1367 | 2 |

| 91 | Incorporating antigen processing into CD4+ T cell epitope prediction with integer linear programming. **2022**, | |

| 90 | Integrated Immunopeptidomics and Proteomics Study Reveals Imbalanced Innate and Adaptive Immune Responses to SARS-Cov-2 Infection. | 1 |

| 89 | Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. **2022**, 13, | 1 |

| 88 | Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. **2022**, 13, | o |

| 87 | Unique and common TCR repertoire features of Ni 2+ -, Co 2+ - and Pd 2+ -specific human CD154 + CD4 + T cells. | o |

| 86 | SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells. | |

| 85 | Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2. **2022**, | o |

| 84 | Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. **2022**, 161-181 | o |

| 83 | High-resolution analysis of individual spike peptide-specific CD4 + T-cell responses in vaccine recipients and COVID -19 patients. **2022**, 11, | o |

| 82 | T cells in SARS-CoV-2 infection and vaccination. **2022**, 10, 251513552211150 | o |

| 81 | Rapid Identification of MHCII-Binding Peptides Through Microsphere-Assisted Peptide Screening (MAPS). **2022**, 233-250 | o |

| 80 | Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era. **2022**, 14, 4252 | o |

| 79 | Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. **2022**, 13, | o |

60	Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2. **2023**, 87, 104401	0
59	Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. **2022**, 10, 1997	0
58	Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity. **2022**, 42,	0
57	SARS-CoV-2 epitopes inform future vaccination strategies. 13,	0
56	SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells. 11,	1
55	Current understanding of T cell immunity against SARS-CoV-2. **2022**, 42,	1
54	Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. **2022**, 23, 14367	0
53	Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients. **2022**, 10, 2117	0
52	A new framework for host-pathogen interaction research. 13,	0
51	SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.	0
50	Donor selection for adoptive cell therapy with CD45RAâ memory T cells for COVID-19 patients, and dexamethasone and interleukin-15 effect on the phenotype, proliferation and interferon gamma release. **2022**,	0
49	Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. **2022**, 23, 15122	0
48	Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.	1
47	Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition. **2022**, 23, 1726-1734	1
46	High titre neutralizing antibodies in response to SARSâCoVâ2 infection require RBDâspecific CD4 T cells that include proliferative memory cells. 13,	0
45	Correlation between Baseline 25(OH) Vitamin D Levels and Both Humoral Immunity and Breakthrough Infection Post-COVID-19 Vaccination. **2022**, 10, 2116	1
44	The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.	0
43	Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model. **2023**, 15, 230	0

42	Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients. 13,	0
41	High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform.	0
40	Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. **2023**, 24, 1701	1
39	Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults. **2023**, 20,	0
38	Prevalent and immunodominant CD8 T-cell epitopes are conserved in SARS-CoV-2 variants. **2023**, 111995	2
37	A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. **2023**, 100388	0
36	Sequence similarity between SARS-CoV-2 nucleocapsid and multiple sclerosis-associated proteins provides insight into viral neuropathogenesis following infection. **2023**, 13,	0
35	Persistent humoral and CD4+ TH cell immunity after mild SARS-COV-2 infection—The CoNAN long-term study. 13,	0
34	SARS-CoV-2 variant biology: immune escape, transmission and fitness.	1
33	Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies.	0
32	Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes. **2023**, 14, 72-83.e5	0
31	Targets and cross-reactivity of human T cell recognition of Common Cold Coronaviruses.	0
30	T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. **2022**, 28, 211-222	0
29	The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. **2023**, 15, 95	0
28	The role of T cell immunity in COVID-19. **2023**, 129-140	0
27	Positive-strand RNA viruses—Keystone Symposia report.	0
26	T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters. 14,	0
25	T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac. **2023**, 24, 1930	0

24	State of the art in epitope mapping and opportunities in COVID-19. **2023**, 9,	0
23	SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design.	2
22	T-cell activationâinduced marker assays in health and disease.	0
21	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. 14,	0
20	Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies.	1
19	T Cell Responses to SARS-CoV-2. **2023**, 41,	1
18	A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine. **2023**, 19,	0
17	SARS-CoV-2 Infection-Blocking Immunity Post Natural Infection: The Role of Vitamin D. **2023**, 11, 475	0
16	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. **2023**, 11, 545	0
15	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. **2023**, 11, 548	0
14	Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. 14,	0
13	Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. **2023**, 95,	1
12	Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain. **2023**, 42, 112256	0
11	SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. 14,	0
10	T cell immunity of the nonadjuvanted HLA-restricted peptide COVID-19 vaccine.	0
9	Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice. **2023**, 15, 763	0
8	Architecture of the SARS-CoV-2-specific T cell repertoire. 14,	0
7	Prediction of the SARS-CoV-2 Derived T-Cell EpitopesâResponse Against COVID Variants. **2023**, 75, 3517-3535	0

6	HLA Variation and SARS-CoV-2 Specific Antibody Response. **2023**, 15, 906	0
5	Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. 14,	0
4	Identification of differentially recognized T cell epitopes in the spectrum ofMtbinfection.	0
3	Antigen-specificity measurements are the key to understanding T cell responses. 14,	0
2	sCXCL16 as a prognostic biomarker for COVID-19 outcome. **2023**, 95,	0
1	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. **2023**, 11, 849	0